Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Pfizer (PFE) Reveals Positive Phase III Data on Trumenba

Pfizer Inc. PFE announced positive results from two phase III studies (one in adolescents and one in young adults) on Trumenba (meningococcal group B vaccine), for providing protection against serogroup B meningococcal disease.

The randomized, placebo-controlled, observer-blinded studies evaluated the immunogenicity of Trumenba against invasive meningococcal B (MnB) strains representative of prevalent strains in adolescents (aged 10–18 years) and in adults (aged 10–25 years).

Secondary data from the studies demonstrated that Trumenba had similar immune responses against 10 additional MnB strains. In addition, the studies met all primary immunogenicity endpoints. These results were presented at the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID).

Results from the phase III studies will support additional upcoming global regulatory submissions on Trumenba and the planned supplemental request in the U.S. to convert the accelerated approval to traditional approval.

We remind investors that in Oct 2014, Trumenba was granted accelerated approval in the U.S. for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals aged between 10 and 25 years.

According to the press release issued by Pfizer, incidence of invasive meningococcal disease ranges from less than 0.5 cases per 100,000 in the U.S., below 1 case per 100,000 in the EU, and up to 10–1,000 cases per 100,000 during the epidemic years in Africa.

Pfizer has a Zacks Rank #2 (Buy). Other favorably ranked stocks in the health care sector include Bristol-Myers Squibb Company BMY, Adaptimmune Therapeutics plc ADAP and ANI Pharmaceuticals, Inc. ANIP, each  sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BRISTOL-MYERS (BMY): Free Stock Analysis Report
 
PFIZER INC (PFE): Free Stock Analysis Report
 
ADAPTIMMUNE THR (ADAP): Free Stock Analysis Report
 
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
 
To read this article on Zacks.com click here.